Integrated pharmaceutical manufacturer
Tasly, founded in April, 1998 and headquartered in Tianjin, is an integrated pharmaceutical manufacturer. The founder is Yan Kaijing. Listed on the SSE on August 23, 2002, the company's major shareholders are Tasly Holdings Group Co., Ltd., China Securities Finance Corporation and Tianjin Heyue Technology Development Partnership (LP). Rivals that have direct and indirect competition with Tasly include Harbin Pharmaceutical, Yunnan Baiyao, Glaxo Smith Kline, Pfizer, etc.
Modern Chinese Medicine Maker Tasly Pharmaceutical: An Old Stock in a New Package?
Tasly Pharmaceutical, founded in 1994 and listed on SSE in 2002, is valued at CNY 26.9 billion – a market cap that the company once achieved ten years ago. But did the company merely spin in circles during the last decade?
Jul 12, 2020 12:00 PM
ResearchReal Estate, Consumer Discretionary, Industrials
Tech for Global, Globalization Footprints of the Established and the New
ResearchConsumer Staples, Industrials, Financials
Low-Carbon Industry Expansion - Key Studies From Chinese Companies
WIM Presents Next 50 in Global Tech: Healthcare
In 2020, as COVID-19 spread around the world, people began to pay more attention to the healthcare industry. The crisis of the pandemic has led directly to significant changes in the healthcare industry across the globe.
Oct 29, 2020 11:00 AM
- Black Swans and Breakthroughs: China's Top 50 Innovative Public Firms in 2020
- China Speed: Two COVID-19 Vaccines Recognized by WHO
- After China's BNR and GTH Hit Nasdaq, Pan-Cancer Detector GRAIL Eyes IPO
- Bid for Molecular Tech in China's Early-Stage Cancer Detection Market
- More Room for the Medical Device Market to Grow in China